These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 34338239

  • 1. Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report.
    Fu L, Chen P, Wang S, Liu W, Chen Z, Chen H, Fu Z.
    Anticancer Drugs; 2022 Jan 01; 33(1):e741-e746. PubMed ID: 34338239
    [Abstract] [Full Text] [Related]

  • 2. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
    Bao Z, Yu X, Zheng K, Zhai K, Cui H, Xu M.
    Front Immunol; 2024 Jan 01; 15():1372279. PubMed ID: 38756778
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.
    Wang X, Sun X, Lei Y, Fang L, Wang Y, Feng K, Xia F.
    BMC Cancer; 2024 Aug 22; 24(1):1036. PubMed ID: 39174912
    [Abstract] [Full Text] [Related]

  • 4. Anlotinib plus Sintilimab achieved in an antitumor effect of complete remission in a patient with advanced hepatocellular carcinoma: a case report.
    Sun C, Ma X, Jiang L, Zhu X.
    Anticancer Drugs; 2024 Apr 01; 35(4):358-361. PubMed ID: 38385998
    [Abstract] [Full Text] [Related]

  • 5. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J, ORIENT-32 study group.
    Lancet Oncol; 2021 Jul 01; 22(7):977-990. PubMed ID: 34143971
    [Abstract] [Full Text] [Related]

  • 6. Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial.
    Han X, Guo J, Li L, Huang Y, Meng X, Wang L, Zhu H, Meng X, Shao Q, Li X, Zhang Y, Wang J, Chen Y, Zhang Y, Chen Y, Zhu C, Wang Z.
    Signal Transduct Target Ther; 2024 Sep 16; 9(1):241. PubMed ID: 39278918
    [Abstract] [Full Text] [Related]

  • 7. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
    Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, Qian J, Zhang Y, Chang Q, Zhang X, Dong Y, Teng J, Gao Z, Qiang H, Nie W, Zhao Y, Han Y, Chen Y, Han B.
    J Thorac Oncol; 2021 Apr 16; 16(4):643-652. PubMed ID: 33524601
    [Abstract] [Full Text] [Related]

  • 8. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Apr 16; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 9. A prospective single-center, single-arm, open-label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer.
    Duan H, Wang Z, Cao L, Zhu Y, Tong L, Yan X.
    Thorac Cancer; 2024 Jul 16; 15(19):1471-1476. PubMed ID: 38770548
    [Abstract] [Full Text] [Related]

  • 10. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S, Xu B, Wu Z, Wang P, Yu W, Liu Z, Huang X, Wu Y, Li T, Guo W.
    BMC Cancer; 2021 Oct 19; 21(1):1126. PubMed ID: 34670506
    [Abstract] [Full Text] [Related]

  • 11. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.
    Liu X, Yi Y.
    Immunotherapy; 2021 Dec 19; 13(17):1387-1393. PubMed ID: 34665016
    [Abstract] [Full Text] [Related]

  • 12. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J, Deng YT, Jiang Y.
    Invest New Drugs; 2021 Apr 19; 39(2):330-336. PubMed ID: 32974853
    [Abstract] [Full Text] [Related]

  • 13. Combination of anlotinib and toripalimab for an advanced biliary tract cancer patient with high Eastern Cooperative Oncology Group performance status: a case report.
    Liu L, Chen B, Tang M, Guo Y, Hou J, Zhou W, Zhu X.
    Anticancer Drugs; 2024 Sep 01; 35(8):752-756. PubMed ID: 38728054
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.
    Qiu X, Lu C, Sha H, Zhu Y, Kong W, Tong F, Wang Q, Meng F, Liu B, Du J.
    Front Immunol; 2024 Sep 01; 15():1210859. PubMed ID: 38361920
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.
    Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Qin YY, Shi J, Guo WX, Lu CD, Zheng YX, Zhou FG, Yan ML, Zhou HK, Liang C, Zhang F, Wei WJ, Lau WY, Li JJ, Liu YF, Cheng SQ.
    Nat Med; 2024 Mar 01; 30(3):708-715. PubMed ID: 38242982
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
    Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y, Huang Z, Huang S, Chen Y, Chen L, Ke M, Li L, Li Z, Pan J, Song Y, Liu R, Chen C.
    J Clin Oncol; 2022 Jun 01; 40(16):1795-1805. PubMed ID: 35192397
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT.
    World J Gastroenterol; 2023 Mar 14; 29(10):1614-1626. PubMed ID: 36970591
    [Abstract] [Full Text] [Related]

  • 18. Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
    Schulte N, Li M, Zhan T, Dreikhausen L, Sollors J, Antoni C, Diehl S, Schoenberg SO, Rahbari N, Reissfelder C, Giordano FA, Ebert MP, Teufel A.
    Z Gastroenterol; 2020 Aug 14; 58(8):773-777. PubMed ID: 32785913
    [Abstract] [Full Text] [Related]

  • 19. Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
    Wang J, Li X, Wang F, Shi D, Zhang J.
    J Cancer Res Ther; 2021 Jul 14; 17(3):619-624. PubMed ID: 34269290
    [Abstract] [Full Text] [Related]

  • 20. Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review.
    Lv C, Wu C, Zhang Y, Li W, Wang X, Liang L.
    Curr Oncol; 2022 Oct 25; 29(11):7987-7993. PubMed ID: 36354692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.